If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, ChinaDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, ChinaDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
CLCA1 is a member of the CLCA (calcium-activated chloride channel regulator) family and plays an essential role in goblet cell mucus production from the respiratory tract epithelium. CLCA1 also regulates Ca2+-dependent Cl− transport that involves the channel protein transmembrane protein 16A (TMEM16A) and its accessary molecules. CLCA1 modulates epithelial cell chloride current and participates in the pathogenesis of mucus hypersecretory-associated respiratory and gastrointestinal diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, colon colitis, cystic fibrosis intestinal mucous disease, ulcerative colitis, and gastrointestinal parasitic infection. Most studies have been focused on the expression regulation of CLCA1 in human specimens. Limited studies used the CLCA1-deficient mice and CLCA1 blocking agents and yielded inconsistent conclusions regarding its role in these diseases. CLCA1 not only regulates mucin expression, but also participates in innate immune responses by binding to yet unidentified molecules on inflammatory cells for cytokine and chemokine production. CLCA1 also targets lymphatic endothelial cells and cancer cells by regulating lymphatic cell proliferation and lymphatic sinus growth in the lymphatic organs and controlling cancer cell differentiation, proliferation, and apoptosis, all which depend on the location of the lymphatic vessels, the type of cancers, the presence of Th2 cytokines, and possibly the availability and type of CLCA1-binding proteins. Here we summarize available studies related to these different activities of CLCA1 to assist our understanding of how this secreted modifier of calcium-activated chloride channels (CaCCs) affects mucus production and innate immunity during the pathogenesis of respiratory, gastrointestinal, and malignant diseases.
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
For example, four human (hCLCA1 to hCLCA4), eight murine (mCLCA1 to mCLCA8), and four bovine (bCLCA1, bCLCA2 (Lu-ECAM-1), bCLCA3, and bCLCA4) CLCA family members have been reported.
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
Indeed, the hCLCA1 ortholog in mice is not mCLCA1, but mCLCA3 and also called goblet cell protein-5 (Gob-5) with a similar expression profile to that of hCLCA1.
Therefore, the nomenclature of this family of proteins has been confusing. To be identified among the species, mouse mCLCA3 (Gob-5) is now renamed as mCLCA1 according to the Human Gene Nomenclature Committee and the Rat Genome Database.
The goblet cell protein Clca1 (alias mClca3 or gob-5) is not required for intestinal mucus synthesis, structure and barrier function in naive or DSS-challenged mice.
Therefore, we use mCLCA1 instead of mCLCA3 or Gob-5 in this review. Despite in mucus-producing diseases, there is scarce information available regarding the pathobiological functions of CLCA1 in humans and animals. This review summarizes the limited functional studies of CLCA1 in respiratory diseases, cancers, and gastrointestinal diseases from humans and experimental models to promote the investigation of this molecule.
Characterization of CLCA1 in the CLCA family
Human hCLCA1 is the first member to be investigated in the family of Ca2+-activated Cl− channel regulators. Its genomic sequence comprises 31,902 base pairs with 15 exons and 14 introns located on the short arm of chromosome 1 (p22–31).
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
In mice, mCLCA1 exhibits a similar expression profile to that of hCLCA1. The murine mCLCA1 gene is located on the respective syntenic locus of chromosome 3 (band H2–H3),
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
Previous investigations have challenged its character as being a Ca2+-dependent Cl− channel itself, largely because of the lack of appropriate membrane-spanning domains based on the algorithm predictions, the absence of attachment to the cell membrane, its localization to the mucin granules during secretion into the extracellular milieu as a globular protein, and functional analysis in nonheterologous cell lines.
Moreover, CLCA1 elevates the conductance of endogenous Ca2+-dependent Cl− channels by lowering the energy barriers for ion translocation through the pore instead of forming Ca2+-dependent Cl− channels per se.
Biochemical and electrophysiological studies demonstrate that hCLCA1 and mCLCA1 are secreted as globular proteins without trans-membrane domains, and they could be removed from the cell surface and identified in the extracellular milieu when expressed in the epithelial cell line HEK293 cells.
They may participate in the extracellular signaling and protein-protein interactions depending on the presence of the von Willebrand factor type A (VWA) and fibronectin type III domains.
Co-expression of the β-subunit KCNMB1 (potassium calcium-activated channel subfamily M regulatory beta subunit 1) with CLCA1 evoked significantly the CaCCs in human embryonic kidney cells, suggesting that the activation of CLCA1 can be adjusted by accessory subunits.
The large conductance potassium channel beta-subunit can interact with and modulate the functional properties of a calcium-activated chloride channel, CLCA1.
Prior studies reported a self-cleavage of the 110-kDa full-length mCLCA1 post-translational product in the endoplasmic reticulum into a 75~90-kDa NH2-terminal and a 35-kDa COOH-terminal proteins that underwent glycosylation,
Transmembrane protein 16A (TMEM16A, also known as anoctamin-1 [ANO1] or discovered on gastrointestinal stromal tumors-1 [DOG1]) was described as the first genuine CaCC in mammals.
CLCA1 is probably the best-studied member from the CLCA family prominently in human respiratory diseases. Human hCLCA1 is a crucial mediator of hypersecretory lung diseases, such as asthma,
cystic fibrosis, and other diseases that manifest increased mucus production. In addition to the modulation of airway mucus secretion, CLCA1 is also involved in the modulation of tissue inflammation in the innate immune response by regulating the production of cytokines and chemokines (Fig. 1). The secreted form of CLCA1 acts as a signaling ligand that activates human monocyte U-937 and primary cultured porcine alveolar macrophages in a dose-dependent manner and increases the expressions of pro-inflammatory interleukin (IL)-1β, IL-6, IL-8 and tumor necrosis factor-α (TNF-α), thereby acting as a pleiotropic factor in lung inflammation.
CLCA1-induced chemokines may initiate the recruitment of inflammatory cells to the respiratory epithelium and lamina propria (Fig. 1). Accordingly, hCLCA1 and its ortholog mCLCA1 in mice have been proposed as a biomarker of inflammatory airway diseases (IAD). These novel biomarkers may help potentiate the treatments of patients with or at high risk of IAD by targeting these human or mouse CLCA1.
Fig. 1CLCA1 in the respiratory system. Expression of CLCA1 is induced in the lung epithelium by T helper 2 (Th2) cytokines, allergen, or house dust mite (HDM) treatment and causes increased mucus production. In addition to mucus secretion modulation, CLCA1 is also an essential regulator of innate immune responses. The secreted form of CLCA1 can act as a signaling ligand that activates monocytes and alveolar macrophages in a dose-dependent manner, increase the levels of pro-inflammatory cytokines and chemokines (IL-1β, IL-6, IL-8 and TNF-α), and initiate the recruitment of inflammatory cells, such as B cells, T cells, neutrophils, and mast cells
Studies have shown that overexpression of hCLCA-1 and the murine mCLCA-1 is essential to mucin overproduction and airway hyperresponsiveness in asthma. hCLCA1 was identified as one of the up-regulated genes with the highest log2 fold change (LFC) (LFC = 2.81) in an integrative analysis of multiple public microarray data sets that aimed to determine differentially expressed genes in asthmatic subjects.
Expression of mCLCA1 was specifically up-regulated in the lung epithelium of IL-9 transgenic mice as well as by intratracheal instillation of IL-9 and other Th2 cytokines (IL-4, IL-13); and the expression of hCLCA1 was also promoted by Th2 cytokine treatment in cultured human primary lung cells, suggesting the participation of hCLCA1 and mCLCA1 in the pathogenesis of Th2 cytokine-mediated asthmatic disorders in humans and experimental models.
The function of CLCA1 is not restricted to Th2 stimuli. Using a house dust mite allergen (HDMA)-induced experimental asthma in cynomolgus macaques, CLCA1 was up-regulated in the bronchoalveolar lavage fluid (BALF) as determined by mass spectrometry; and significantly reduced in the same challenged but corticosteroid-treated animals.
Repeated intranasal administration of cerium dioxide nanoparticles (CeO2NPs) in the presence of HDM initiated a type 2 immune response in mice, which presented within asthmatic endotypes and accompanied by increases of mucin and inflammatory regulator mCLCA1.
By examining the gene expression patterns in ovalbumin (OVA)-sensitized and -challenged male Balb/c mice, mCLCA1 mRNA was induced specifically in the murine lung tissue with airway hyperresponsiveness.
mCLCA1 gene expression silencing with the adenovirus expressing mCLCA1 antisense RNA inhibited the bronchial hyperreactivity and mucus hypersecretion. Meanwhile, overexpression of the mCLCA1 gene by administrating adenovirus containing the mCLCA1 gene intratracheally aggravated the murine asthma phenotype, including eosinophil infiltration, goblet cell metaplasia, excessive mucus production, and bronchial hyperreactivity.
OVA-challenged mCLCA1-deficient Clca1−/− mice showed decreased peri-vascular tissue inflammation, goblet cell hyperplasia, mucus production, as well as decreased airway hyperresponsiveness after cholinergic provocation with methacholine.
mCLCA1 antibody treatment remarkably reduced airway inflammation and goblet cell numbers in lung tissue, and promoted goblet cell apoptosis with increased production of Bax and decreased expression of Bcl-2 in goblet cells. mCLCA1 antibody significantly reduced the production of mucin 5AC (MUC5AC, the major respiratory mucin in goblet-cell secretion
Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells.
Collectively, mCLCA1 presents an essential activity in murine asthma, and its human counterpart hCLCA1 may become an effective therapeutic target for asthma.
Yet, the allergic response produced by acute intranasal IL-13 instillation or OVA challenge was similar in Clca1−/− mice and their wild-type (WT) littermates from a different but similar study, which demonstrated that the expression of mCLCA1 is not required for mucin hypersecretion regulated by pro-inflammatory signals in mice.
Similar to the observations from Clca1−/− mice, siRNA transfection-mediated knockdown of the hCLCA1 gene expression in human lung epithelial cell line (NCI–H292) failed to reduce the MUC5AC mRNA level or protein production.
Contradictory observations from these different studies have made the roles of CLCA1 in mucus overproduction and asthmatic responses inconclusive.
Chronic obstructive pulmonary disease
COPD is a chronic inflammatory lung disease with features of goblet cell hyperplasia and mucus overproduction. Twenty-two novel single nucleotide polymorphisms (SNPs) of the hCLCA1 gene were identified in COPD subjects from Japanese and Egyptian populations that might be effective for anticipating the susceptibility to COPD.
Real-time quantitative PCR analyses revealed higher hCLCA1 mRNA level in hypertonic saline-stimulated sputum cells from COPD patients, compared with those of non-smoker controls (P = 0.02). Immunostaining with an anti-hCLCA1 antibody showed prominent hCLCA1 production in the bronchioles and terminal bronchioles epithelia in COPD patients.
Increased human Ca(2)(+)-activated Cl(-) channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients.
Therefore, targeting hCLCA1 might have potential clinical benefits to COPD patients, although a direct role of CLCA1 in COPD has not been tested.
Fig. 2CLCA1 on mucus production. Th2 cytokine IL-13 binds to the IL-13 receptor and leads to increased expression of CLCA1 via the STAT6/SPDEF signaling/transcription pathway. The 110-kDa full-length CLCA1 translational product in the endoplasmic reticulum undergoes self-cleavage by releasing the 35-kDa COOH-terminal fragment and allowing the 75~90-kDa NH2-terminal protein to bind to a putative yet undefined receptor on the airway epithelial cell surface, followed by activation of the MAPK13 signaling pathway and mucin gene expression
Cystic fibrosis (CF) is a frequent autosomal recessive disorder induced by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a cyclic adenosine monophosphate (cAMP)-dependent chloride channel.
The percentages of hCLCA1-positive epithelial cells (nasal polyps, 93.8% ± 7.2%; nasal mucosa, 85.4% ± 12.3%; sinus mucosa, 71.4% ± 18.7%) were significantly higher in the epithelium of patients with CF compared with that of control subjects (20.8% ± 15.1%; P < 0.05).
Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis.
Stimulation with Th2 cytokines IL-4, IL-9, and IL-13 significantly increased the hCLCA1 protein expression (P < 0.05) in mucosal tissue explant from the CF patient upper airways, while MUC5AC mRNA and mucin protein levels were not significantly altered, which questioned the role of hCLCA1 as a mediator of mucus hypersecretion in CF.
The mCLCA1 mRNA is readily detected by northern blot analysis and by in situ hybridization in the respiratory epithelia of trachea and bronchi as well as epithelia of their submucosal glands.
However, whether the secreted CLCA1 proteins interact directly or indirectly with either the CFTR protein or others as yet unidentified channel protein via a receptor-mediated pathway remains unknown.
Therefore, the mechanism of suspected modulatory functions of CLCA1 in CF is far from being resolved.
Prior studies showed that the mRNA level of mCLCA1 is not differentially regulated in the respiratory tract of murine experimental CF compared with WT controls.
Basal bioelectric measurements failed to reveal any significant differences in basal short-circuit current, amiloride-sensitive Na+ absorption, cAMP-dependent Cl− secretion, and activation of Ca2+-activated (uridine-5′-triphosphate-mediated) Cl− secretion in Clca1−/− mice compared with WT mice.
Intratracheal administration of IL-13 generated an approximately 30-fold up-regulation of the mCLCA1 transcripts without inducing the CaCCs activity in WT mouse airways, and induced goblet cell hyperplasia and mucin gene expression to the similar levels in both genotypes.
Reverse-transcription quantitative PCR assay did not detect significant changes in the expression of other CaCC candidates that may compensate for a lack of mCLCA1 function, including seven mCLCAs, mBEST1, mBEST2, mCLC4, mTMEM16A, and mTTYH3, in the lung between Clca1−/− and WT mice.
These findings argue against the function of mCLCA1 in mediating its CF-modulatory role through CaCC conductances in murine respiratory epithelia. Therefore, like in asthma, the role of mCLCA1 in CF also remains inconclusive.
Pneumonia
Bacterial Staphylococcus aureus (S. aureus) infection induces pneumonia. Female Clca1−/− mice that were transnasally inoculated with S. aureus showed decreased neutrophil recruitment to the bronchoalveolar space and decreased mRNA and protein levels of IL-17 and murine C-X-C motif chemokine ligand 1 (CXCL-1) compared to those from infected WT controls. It was suggested that mCLCA1 modulated the leukocyte accumulation via induction of IL-17 and CXCL-1 in bacterial pneumonia and appeared to have an effect on the early innate immune response following S. aureus lung infection.
Yet, mCLCA1-deficiency did not affect mucus cell number and mucin secretion in infected mice. In murine experimental acute pneumonia induced by S. aureus infection, the expression of airway mucus component bactericidal/permeability-increasing protein (BPI) fold-containing family A member 1 (Bpifa1), a secretory protein from the respiratory tract that has antimicrobial and anti-biofilm properties to regulate mucociliary clearance,
Soluble mucus component CLCA1 modulates expression of leukotactic cytokines and BPIFA1 in murine alveolar macrophages but not in bone marrow-derived macrophages.
Therefore, the role of CLCA1 in respiratory diseases might involve much more complicated downstream pathways, rather than just goblet cell mucus production and epithelial cell chloride ion secretion.
Mucin synthesis
Mucus overproduction contributes to airway inflammation and obstruction. Previous studies showed that Th2 cytokine IL-13 receptor activation led to the activation of the IL-13 signaling molecule STAT6 (signal transducer and activator of transcription 6)
and consequent induction of CLCA1 gene expression, and associated with the secretion of MUC5AC in airway epithelial cells. Specific knockdown of transcription factor SPDEF (sterile alpha motif [SAM] domain-containing prostate-derived Ets transcription factor) suppressed IL-13-induced MUC5AC production in human airway epithelial cells. Repression of STAT6 prohibited the production of IL-13-induced SPDEF and MUC5AC. Therefore, IL-13 induces MUC5AC production via the STAT6/SPDEF signaling and transcription pathway in human airway epithelial cells (Fig. 2).
proposing a possibility of preventing mucus overproduction in chronic airway inflammatory diseases by targeting the STAT6/SPDEF signaling and transcription pathway.
Cigarette smoke-induced mucin production
Immunostaining of airway epithelium with an anti-hCLCA1 antibody demonstrated significant enhancement of hCLCA1 expressin in smokers without COPD (P = 0.02) compared with that in non-smokers.
Increased human Ca(2)(+)-activated Cl(-) channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients.
Cigarette smoke-exposed Sprague-Dawley rats showed significant up-regulation of rat CLCA1, epidermal growth factor receptor (EGFR), and MUC5AC in the trachea and lung tissues as well as the numbers of goblet cells in the tracheal epithelium from day 21 onwards than those from the non-smoking group (P < 0.001).
Niflumic acid (NFA, blocker of the CLCAs), AG-1478 (inhibitor of EGFR tyrosine kinase), or combination of the two inhibited the smoke-induced MUC5AC gene expression.
Cigarette smoke markedly influenced the IL-13-induced Th2-signature gene expression and reduced hCLCA1 and MUC5AC expression in air-liquid interface differentiated human bronchial (ALI-PBEC) and tracheal epithelial cells (ALI-PTEC).
Both in vivo and in vitro studies demonstrated an essential role for CLCA1 in cigarette smoke-induced mucin synthesis. The activity of cigarette smoke in promoting mucin expression may vary depending on the presence of Th2 cytokines.
TNF-α–induced mucin expression
In an ex vivo model of human upper airway mucosa, stimulation with TNF-α (10 ng/mL) for 24 hours also significantly increased the hCLCA1 and MUC5AC mRNA levels as well as hCLCA1 and mucus protein levels.
Blocking hCLCA1 functions with chloride channel blockers (NFA and MSI-2216) reduced the MUC5AC mRNA levels and mucus protein expression in a dose-dependent manner.
This study suggests that inhibition of hCLCA1 is potentially a novel approach to inhibit mucus expression. Specific blockers to target hCLCA1 may have significant clinical value and merit further investigation.
Roles of CLCA1 in cancer progression
Results from previous studies have documented close association of CLCA1 with cancer progression.
A genetic study using fixed colorectal carcinoma samples also indicated a negative association between hCLCA1 level and the cancer stage. Each colorectal carcinoma stage increase reduced the hCLCA1 by 3.1 folds.
Yet, evidence from ovarian cancer analysis revealed that CLCA1 was overexpressed during cancer progression, as determined by both RT-PCR and immunoblot analyses. hCLCA1 silence with siRNA blocked the ovarian cancer cells multicellular aggregates.
Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1).
Therefore, the role of CLCA1 in tumor progression may depend on the types of tumors. Further understanding of how CLCA1 exerts its function in different metastatic progression patterns across major human cancers and how CLCA1 affects cancer cell resistance to chemotherapeutic drugs may lead the identification of potential therapeutic targets and development of effective approaches to treat these relevant cancers.
CLCA1 in ovarian cancer
Comparative proteomics analysis revealed an increased expression of hCLCA1 in an ovarian cancer cell line OV-90 and cell models of tumor aggregate formation (TOV-112D and ES-2).
Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1).
During the process of ovarian cancer metastasis, detached cancerous cells tend to form multicellular aggregates that facilitate ovarian cancer metastasis both by breaching the mesothelium and initiating widespread peritoneal dissemination.
Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1).
These findings indicate that hCLCA1 plays an essential role in promoting ovarian cancer metastasis, although further experimental validation is required to characterize the function of CLCA1 in the pathogenesis of ovarian cancer.
CLCA1 in human colorectal cancer
Different from what was reported in the ovarian cancer cells, a proteogenomic study applying mass spectrometry and gene microarray in both human colorectal cancer and adjacent normal mucosa tissues confirmed reduced expression of hCLCA1 in the colorectal cancer tissue.
indicating that hCLCA1 may serve as a potential biomarker of human colorectal cancer. Low levels of hCLCA1 expression in the colonic epithelial tissues correlated with a less differentiated tumor histological grade, an advanced tumor stage, metastases in regional lymph nodes, and high Dukes stage that has been used to grade colon cancer based on cancer cell locations from the mucosa, muscle layer, to lymph node, and distant metastasis. Patients with low hCLCA1 expression levels had significantly poorer overall survival rate and higher recurrence rate than those with high levels of hCLCA1 expression (P < 0.05).
Results from a clearly-defined cohort of patients with rectal cancer who received concurrent chemoradiotherapy before tumor resection surgery implied that high levels of hCLCA1 associated significantly with higher pre-treatment tumor nodal stages, inferior tumor regression grade, and vascular invasion.
High immunohistochemical expression of hCLCA1 also predicted shorter survivals in patients with rectal cancer who received concurrent chemoradiotherapy before surgery.
hCLCA1 expression is up-regulated in sodium butyrate-differentiated human intestinal cancer cell line Caco-2. hCLCA1 knockdown with siRNA inhibited Caco-2 cell differentiation but promoted cell proliferation. Therefore, hCLCA1 may serve as a useful diagnostic biomarker for colorectal cancer prognosis.
Loss of CLCA1 expression prevents enterocyte differentiation and may promote colonic cancer progression. Up-regulation of hCLCA1 suppressed colorectal cancer progression and metastasis in vivo and in vitro, whereas blocking hCLCA1 expression led to the opposite phenotypes.
Elevated expression levels of hCLCA1 repressed the Wnt/β-catenin signaling as well as the epithelial-mesenchymal transition (EMT) process in colorectal cancer cells, suggesting that hCLCA1 acted as a tumor suppressor in colorectal cancer by suppressing the Wnt/β-catenin signaling pathway and EMT process.
Indeed, immunohistochemical analysis of human cancerous colonic epithelial tissues reveals positive correlation between hCLCA1 staining with E-cadherin and tumor suppressor p53.
All these studies support both the therapeutic and prognostic potential of hCLCA1 in rectal cancers, although the mechanisms by which hCLCA1 suppresses tumor growth may beyond inhibiting the Wnt/β-catenin signaling network and EMT process.
CLCA1 in lung cancer
B16–F10 melanoma cells are characterized by robust surface expression of β4 integrin
and consistent high lung colonization potential. Previous studies demonstrated that glutathione S-transferase fusion proteins of β4-binding motifs (β4BMs) from the 90- and 35-kDa mCLCA1 subunits bound to the β4 integrin in a metal ion-dependent manner.
The β4 integrin-mCLCA1 interaction led to complex formation with and activation of the downstream focal adhesion kinase (FAK)/extracellular signal-regulated kinase (ERK) signaling, and promoted early, intravascular, and metastatic growth.
Different from aforesaid in colorectal cancer, however, mCLCA1 in lung cancer appears to play a positive role by promoting cancer cell migration and metastasis after binding to the β4 integrin.
CLCA1 in gastrointestinal diseases
In the gastrointestinal tract, CLCA1 is expressed predominantly in the small intestine, colon, and appendix. As a goblet cell secretory protein from the respiratory tract, CLCA1 can also present as a secretory protein and perform important functions in intestinal mucus dynamics and homeostasis.
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system.
The localization of mCLCA1 protein in salivary duct cells, parietal cells, and epithelial cells of the small intestinal crypts as well as on the pancreatic zymogen granule membrane favors a cell type-specific function of mCLCA1 contributing to transepithelial ion transport and protein secretion.
Further understanding of CLCA1 function in mucus production helps probe the pathophysiology of gastrointestinal diseases and develop novel treatment for mucus production-associated complications by regulating CLCA1 expression.
CLCA1 in murine dextran sodium sulfate-induced colitis
To analyze the role of CLCA1 in the pathogenesis of murine dextran sodium sulfate (DSS)-induced colitis, mCLCA1-deficient Clca1−/− mice (C57BL/6J background) and WT (same genetic background) mice under unchallenged or DSS-challenged conditions at different time points were compared. Lack of mCLCA1 correlated with a more than two-fold increase of IL-17 and CXCL-1 mRNA in the distal colon during the development of DSS-induced colitis, similar to what was reported from S. aureus-induced pneumonia, although accumulation of neutrophils, macrophages, and lymphocytes in the proximal and distal colon following colitis induction did not differ between Clca1−/− and WT mice. Further, no difference was found between Clca1−/− and WT mice under unchallenged or DSS-challenged conditions in terms of clinical parameters, disease progression or outcome, and key histopathological parameters such as epithelial defects and regeneration.
Similarly, when comparing Clca1−/− and WT mice under naive and at different time points of DSS-challenged conditions, expression of the major intestinal mucin MUC2 and mucus structure, or other essential components of the mucus including Agr2, Fcgbp, Klk1 and Zg16, or mucus growth rate, thickness, and penetrability also did not differ. DSS challenge identically affected the mucus barriers, bacterial translocation, fecal microbiota composition, fecal blood content and stool consistency scores of Clca1−/− and WT mice, suggesting that CLCA1 is not required for mucus synthesis, structure and barrier function in murine colon.
The goblet cell protein Clca1 (alias mClca3 or gob-5) is not required for intestinal mucus synthesis, structure and barrier function in naive or DSS-challenged mice.
This discrepancy with the results of CLCA1 function in the lung highlights the different effects of the type of challenges and tissue environment on the roles of CLCA1.
CLCA1 in cystic fibrosis intestinal mucous disease
CLCA1 is important for the function of intestinal goblet cell, including adjustment of the mucous properties or secretion that is changed in CF intestinal disease. A significant correlation between allelic variants at the human hCLCA1 gene locus and CFTR-independent chloride conductance was found in rectal mucosa biopsies from CF subjects.
In TgrIFABP-mCLCA1 transgenic mice, where mCLCA1 expression was driven by the rat intestinal fatty acid binding protein promoter (rIFABP) that is specific to intestinal enterocytes and goblet cells,
Goblet cells were significantly larger in the intestine of TgrIFABP-mCLCA1 CF mice than WT CF mice, and the number of goblet cells per villus in the TgrIFABP-mCLCA1 CF mouse ileum was significantly elevated over the control mice with CF alone, supporting a role of mCLCA1 in goblet cell hypertrophy and hyperplasia. Together, these results suggest that mCLCA1 also displays activities in controlling mucous properties and secretion during the pathogenesis of intestinal mucous diseases.
Secreted (extracellular) mCLCA1 may inhibit goblet cell degranulation as a negative feedback mechanism to control the expression of extracellular mucus.
CLCA1 in ulcerative colitis
Ulcerative colitis is an inflammatory disease of the colonic mucosa caused by a sustained deregulation of the intestinal epithelial barrier function.
Whole genome expression analysis revealed that a group of genes was differentially regulated in the epithelial organoid cultures (EpOCs) and differentiated EpOCs (d-EpOCs) in patients with ulcerative colitis,
including a marked down-regulation of hCLCA1, which is a major component of the mucus produced mainly by secreting cells of the distal digestive tract.
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system.
A loss of hCLCA1 protein expression was also sporadically detected in the colonic epithelium of whole intestinal samples from subjects with ulcerative colitis.
Acidic mammalian chitinase (AMCase) is a major digestive enzyme that constitutively degrades chitin substrates and produces (GlcNAc)2 fragments in mouse gastrointestinal environment. AMCase is known to be induced by allergens and helminthes. AMCase-deficient mice showed a profound deficiency in type 2 immunity following infection with the chitin-containing gastrointestinal nematodes Nippostrongylus brasiliensis and Heligmosomoides polygyrus bakeri. This impaired immunity was correlated with attenuated mucus synthesis and reduced intestinal expression of the signature type 2 immune response genes Chil3, Clca1, Il13, and Retnlb, indicating that AMCase acts as a crucial initiator of protective type 2 immune responses to intestinal nematode infection in the gastrointestinal tract.
The mucous cell-associated CLCA1 transcript was also one of the most up-regulated transcripts observed from immunized sheep in response to infection from ovine gastric nematode Teladorsagia circumcincta.
Lymph nodes undergo extensive architectural remodeling during immune responses. It involves expansion of the lymphatic sinuses (lymphangiogenesis) accompanied by up-regulated stromal components, including lymphatic endothelial cells (ECs), blood ECs, fibroblast reticular cells, and CD4–CD8– double negative T cells.
A hamster monoclonal antibody 10.1.1 recognized lymphatic endothelial mCLCA1. This antibody identified mCLCA1 as a 90-kDa cell-surface protein from lymphatic endothelium and stromal cells within mouse spleen and thymus. mCLCA1 serves as a lymphatic endothelial surface ligand by binding to the β2-integrins LFA-1 (lymphocyte function-associated antigen 1) and Mac-1 that are preferentially expressed on granulocytes, NK cells, dendritic cells, and macrophages, and mediate the adhesion of Mac-1- or LFA-1-positive leukocytes to lymphatic ECs and lymph node lymphatic sinuses (Fig. 3).
Expression of mCLCA1 on lymphatic ECs was not affected by TNF-α/IL-1β stimulation, indicating that mCLCA1 is a constitutive biomarker of normal and inflamed lymphatic ECs.
Antibody 10.1.1 induction of lymph node lymphatic EC proliferation and lymphatic sinus growth appears to be a specific consequence of antibody binding to mCLCA1 on lymph node lymphatic ECs. Antibody 10.1.1-induced lymphangiogenesis was restricted to lymph nodes, as mCLCA1-expressing lymphatic vessels of the jejunum and dermis were unaffected at 23 h after antibody 10.1.1 treatment.
Taken together, these results established a crucial function of mCLCA1 in coordinating lymph node remodeling during immune responses and suggest a new strategy for a therapeutic manipulation of the immune responses.
Fig. 3CLCA1 from the lymphatic endothelium. CLCA1 can serve as a lymphatic endothelial surface ligand by binding to the β2 integrins LFA-1 and Mac-1 that are preferentially expressed on macrophages, and play a role between lymphatic cell and immune cell interactions
CLCA1 as a regulator of Ca2+-activated chloride ion transport on epithelial cells, mucin expression from goblet cells, cytokine and chemokine expression from monocytes and macrophages, tumor cell migration and metastasis, and proliferation of lymphatic ECs, it has been tested in respiratory diseases, gastrointestinal diseases, cancers, and lymphatic tissue remodeling in humans and experimental models (Table 1). Some confusing but potentially important observations are that the same CLCA1 acted differently from different types of cancers and the similar asthma studies yielded contradictory observations. Although limited amounts of work have been carried to test a direct role of CLCA1 in these diseases using the mCLCA1-deficient Clca1−/− mice, observations from conventional biochemical and immunological studies proposed several possible mechanisms by which CLCA1 participate in these diseases. The pathobiological activities of CLCA1 may vary depending on the environment of different types of diseases, the presence of type 2 cytokines, and very interestingly the types of integrins or other accessary proteins. CLCA1 was initially identified as a Ca2+-dependent chloride secretion channel protein, but it does not contain traditional transmembrane domains and it is found secreted as a globular protein. The VWA domain of secreted CLCA1 modulates the activity of CaCC TMEM16A by directly engaging the channel at the cell surface to increase Ca2+-dependent chloride currents in human cells.
The large conductance potassium channel beta-subunit can interact with and modulate the functional properties of a calcium-activated chloride channel, CLCA1.
Combination of CLCA1 with these different accessary proteins may explain the observations from different cancers and mouse respiratory disease models that we discussed in this review. Therefore, mechanistic studies using mCLCA1-deficient mice, cells lines, or specific CLCA1 blocking agents together with modern techniques may help us recognize the importance of this mysterious regulator of CaCCs in human pathobiology. Yet, as discussed above, there are eight mouse mCLCA genes and four human hCLCA genes. These multiple CLCA family members in humans or mice may exhibit certain levels of functional redundancy in the pathogenesis of human diseases or in mouse disease models, which can make it difficult to study the precise functions of CLCA1 in humans and mice even with the development of mouse models mCLCA1 deficiency. Nevertheless, further studies from cultured cells and disease models may help explore the mechanisms by which this secreted protein modulates chloride channels, goblet cell hyperplasia, and innate immune responses.
Table 1Roles of CLCA1 in different diseases.
Disease type
Disease name
Proposed Function of CLCA1
Possible Mechanism of CLCA1
Asthma
Involves in mucin hypersecretion and airway hyper-responsiveness
Soluble mucus component CLCA1 modulates expression of leukotactic cytokines and BPIFA1 in murine alveolar macrophages but not in bone marrow-derived macrophages.
Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1).
The goblet cell protein Clca1 (alias mClca3 or gob-5) is not required for intestinal mucus synthesis, structure and barrier function in naive or DSS-challenged mice.
The goblet cell protein Clca1 (alias mClca3 or gob-5) is not required for intestinal mucus synthesis, structure and barrier function in naive or DSS-challenged mice.
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system.
CLL drafted the manuscript; GPS critically revised the manuscript before submission. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Declaration of competing interest
The authors declare no conflicts of interest and agree to publish the work.
Acknowledgements
This study is supported by awards from the American Heart Association (17POST33670564 to CLL) and the National Institute of Health [HL123568, HL60942, and AG058670 to GPS].
References
Cunningham S.A.
Awayda M.S.
Bubien J.K.
et al.
Cloning of an epithelial chloride channel from bovine trachea.
Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins.
The goblet cell protein Clca1 (alias mClca3 or gob-5) is not required for intestinal mucus synthesis, structure and barrier function in naive or DSS-challenged mice.
The large conductance potassium channel beta-subunit can interact with and modulate the functional properties of a calcium-activated chloride channel, CLCA1.
Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells.
Increased human Ca(2)(+)-activated Cl(-) channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients.
Increased expression of interleukin-9, interleukin-9 receptor, and the calcium-activated chloride channel hCLCA1 in the upper airways of patients with cystic fibrosis.
Soluble mucus component CLCA1 modulates expression of leukotactic cytokines and BPIFA1 in murine alveolar macrophages but not in bone marrow-derived macrophages.
Comparative proteomics of ovarian cancer aggregate formation reveals an increased expression of calcium-activated chloride channel regulator 1 (CLCA1).
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system.
31233-5&id=gr1.jpg){kind=link}
31233-5&id=gr2.jpg){kind=link}
31233-5&id=gr3.jpg){kind=link}